Advanced Recurrent Ovarian Cancer Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential

DelveInsight's, "Advanced Recurrent Ovarian Cancer Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Advanced Recurrent Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Advanced Recurrent Ovarian Cancer Pipeline? Click here to explore the therapies and trials making headlines @ Advanced Recurrent Ovarian Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Advanced Recurrent Ovarian Cancer Pipeline Report

* On 28 August 2025, Allarity Therapeutics announced a study is to evaluate the optimal dose of 2X-121 as single agent therapy at 600 mg daily (split BID 200 mg morning + 400 mg evening) compared to 800 mg daily (split BID 400 mg morning + 400 mg evening) in recurrent, advanced ovarian cancer patients that have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible. The optimal dose will be selected based on an integrated analysis of PK/PD, safety, and efficacy data.
* On 27 August 2025, TCR2 Therapeutics conducted a phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently evaluate the efficacy of gavo-cel, with and without immuno-oncology agents, in patients with advanced mesothelin-expressing cancers, with overall response rate and disease control rate as the primary Phase 2 endpoints.
* DelveInsight's Advanced Recurrent Ovarian Cancer pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Advanced Recurrent Ovarian Cancer treatment.
* The leading Advanced Recurrent Ovarian Cancer Companies such as Allarity Therapeutics, AP Biosciences Inc., A2 Biotherapeutics Inc., Verismo Therapeutics, Accent Therapeutics and others.
* Promising Advanced Recurrent Ovarian Cancer Therapies such as OSI-211 (Liposomal Lurtotecan), Pembrolizumab, Aflibercept, NGR-hTNF, doxorubicin , and others.

Want to know which companies are leading innovation in Advanced Recurrent Ovarian Cancer? Dive into the full pipeline insights @ Advanced Recurrent Ovarian Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Advanced Recurrent Ovarian Cancer Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Advanced Recurrent Ovarian Cancer Pipeline Report also highlights the unmet needs with respect to the Advanced Recurrent Ovarian Cancer.

Advanced Recurrent Ovarian Cancer Overview

Advanced Recurrent Ovarian Cancer is the leading cause of death in women diagnosed with gynecological cancers. It is also the fifth most frequent cause of death in women, in general. Most of the cases are diagnosed at an advanced stage, which leads to poor outcomes of this disease. The existing screening tests have a low predictive value contributing further to this misery. Detailed gynecological evaluation along with ultrasound and laboratory marker like cancer antigen-125 (CA-125) assay are the key early detection strategies which have shown no significant beneficial effect in the morbidity or mortality of this cancer.

Advanced Recurrent Ovarian Cancer Emerging Drugs

* 2X-121: Allarity Therapeutics

Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the Wnt signaling pathway. Aberrant Wnt/-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking Wnt pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic. Allarity has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. Some approved PARP inhibitors have recently been shown to be associated with less favorable survival outcomes than initially established. Allarity's Phase II trial data for stenoparib to date shows that the drug has much less myelotoxicity than the FDA approved PARP inhibitors. Currently, the drug is in the Phase II stage of its development for the treatment of Advanced Recurrent Ovarian Cancer.

* A2B694: A2 Biotherapeutics Inc.

A2B694 is a Tmod Trademark chimeric antigen receptor (CAR) T cell therapy targeting tumors that express mesothelin (MSLN) but lack the HLA-A*02 antigen. A2B694 is the second autologous cell therapy in clinical development by A2 Bio using its proprietary Tmod Trademark platform. The Tmod Trademark platform utilizes a dual-receptor design consisting of an activator that targets tumor cells and a blocker that protects normal cells. This dual-receptor design is intended to provide selective killing of tumor tissues that express mesothelin and have lost the HLA-A*02 gene permanently. This novel design is aimed at tackling the fundamental challenge in solid tumor cancer medicines - the ability to selectively kill tumor cells and protect normal cells. Currently, the drug is in Phase I/II stage of its development for the treatment of Advanced Recurrent Ovarian Cancer.

* ATX-295: Accent Therapeutics

Accent's ATX-295 program is a potential best-in-class inhibitor for KIF18A which may address a large patient population across several cancer indications, including ovarian and triple negative breast cancer (TNBC). KIF18A is a mitotic kinesin motor protein critical for cell division in select tumors with chromosomal instability, but not in healthy cells. KIF18A inhibitor treatment results in rapid cell death for cancers with an abnormal number of chromosomes (aneuploid) in vitro and in vivo, while cells with normal numbers of chromosomes (euploid) are unaffected. Currently, the drug is in Phase I stage of its development for the treatment of Advanced Recurrent Ovarian Cancer.

If you're tracking ongoing Advanced Recurrent Ovarian Cancer Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Advanced Recurrent Ovarian Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Recurrent Ovarian Cancer Companies

Allarity Therapeutics, AP Biosciences Inc., A2 Biotherapeutics Inc., Verismo Therapeutics, Accent Therapeutics and others.

The Advanced Recurrent Ovarian Cancer Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Recurrent Ovarian Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Recurrent Ovarian Cancer Treatment.
* Advanced Recurrent Ovarian Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Advanced Recurrent Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Recurrent Ovarian Cancer market.

Advanced Recurrent Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Advanced Recurrent Ovarian Cancer Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Advanced Recurrent Ovarian Cancer Pipeline Report covers it all - check it out now @ Advanced Recurrent Ovarian Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Advanced Recurrent Ovarian Cancer Pipeline Report

* Coverage- Global
* Advanced Recurrent Ovarian Cancer Companies- Allarity Therapeutics, AP Biosciences Inc., A2 Biotherapeutics Inc., Verismo Therapeutics, Accent Therapeutics and others.
* Advanced Recurrent Ovarian Cancer Therapies- OSI-211 (Liposomal Lurtotecan), Pembrolizumab, Aflibercept, NGR-hTNF, doxorubicin , and others.
* Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Advanced Recurrent Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in oncology research - discover what's next for the Advanced Recurrent Ovarian Cancer Treatment landscape in this detailed analysis @ Advanced Recurrent Ovarian Cancer Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/advanced-recurrent-ovarian-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Advanced Recurrent Ovarian Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Advanced Recurrent Ovarian Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug Name: Company Name
* Mid Stage Products (Phase II)
* 2X-121: Allarity Therapeutics
* Early Stage Products (Phase I)
* ATX-295: Accent Therapeutics
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Advanced Recurrent Ovarian Cancer Key Companies
* Advanced Recurrent Ovarian Cancer Key Products
* Advanced Recurrent Ovarian Cancer- Unmet Needs
* Advanced Recurrent Ovarian Cancer- Market Drivers and Barriers
* Advanced Recurrent Ovarian Cancer- Future Perspectives and Conclusion
* Advanced Recurrent Ovarian Cancer Analyst Views
* Advanced Recurrent Ovarian Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-recurrent-ovarian-cancer-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.